Article ; Online: Targeting the Complement Pathway in Kidney Transplantation.
Journal of the American Society of Nephrology : JASN
2023 Volume 34, Issue 11, Page(s) 1776–1792
Abstract: The complement system is paramount in the clearance of pathogens and cell debris, yet is increasingly recognized as a key component in several pathways leading to allograft injury. There is thus a growing interest in new biomarkers to assess complement ... ...
| Abstract | The complement system is paramount in the clearance of pathogens and cell debris, yet is increasingly recognized as a key component in several pathways leading to allograft injury. There is thus a growing interest in new biomarkers to assess complement activation and guide tailored therapies after kidney transplantation (KTx). C5 blockade has revolutionized post-transplant management of atypical hemolytic uremic syndrome, a paradigm of complement-driven disease. Similarly, new drugs targeting the complement amplification loop hold much promise in the treatment and prevention of recurrence of C3 glomerulopathy. Although unduly activation of the complement pathway has been described after brain death and ischemia reperfusion, any clinical attempts to mitigate the ensuing renal insults have so far provided mixed results. However, the intervention timing, strategy, and type of complement blocker need to be optimized in these settings. Furthermore, the fast-moving field of ex vivo organ perfusion technology opens new avenues to deliver complement-targeted drugs to kidney allografts with limited iatrogenic risks. Complement plays also a key role in the pathogenesis of donor-specific ABO- and HLA-targeted alloantibodies. However, C5 blockade failed overall to improve outcomes in highly sensitized patients and prevent the progression to chronic antibody-mediated rejection (ABMR). Similarly, well-conducted studies with C1 inhibitors in sensitized recipients yielded disappointing results so far, in part, because of subtherapeutic dosage used in clinical studies. The emergence of new complement blockers raises hope to significantly reduce the negative effect of ischemia reperfusion, ABMR, and nephropathy recurrence on outcomes after KTx. |
|---|---|
| MeSH term(s) | Humans ; Kidney Transplantation/adverse effects ; Kidney/pathology ; Transplantation, Homologous ; Complement Activation ; Complement System Proteins ; Isoantibodies ; Ischemia/pathology ; Graft Rejection/prevention & control |
| Chemical Substances | Complement System Proteins (9007-36-7) ; Isoantibodies |
| Language | English |
| Publishing date | 2023-07-13 |
| Publishing country | United States |
| Document type | Journal Article |
| ZDB-ID | 1085942-1 |
| ISSN | 1533-3450 ; 1046-6673 |
| ISSN (online) | 1533-3450 |
| ISSN | 1046-6673 |
| DOI | 10.1681/ASN.0000000000000192 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 3344: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.